North America Nuclear Medicine & Stable Isotopes Market Outlook 2025-2035
The North America Nuclear Medicine & Stable Isotopes Market is experiencing significant expansion driven by technological innovations and a rising prevalence of chronic diseases. Nuclear medicine leverages radioactive substances for diagnosis, treatment, and research, with stable isotopes used extensively in various industrial and medical applications. This market encompasses diagnostic techniques like PET and SPECT, therapeutic radioisotopes, and the distribution and use of stable isotopes in both research and industry. Several factors—including increased adoption of advanced imaging, personalized medicine, and new radiopharmaceutical approvals—are fueling market growth, while challenges around supply chains, regulatory compliance, and high initial costs present persistent hurdles. With a robust healthcare infrastructure and substantial investments from leading players, North America is well-positioned to maintain its market dominance through to 2035.
Latest Market Dynamics
Key Drivers
- Adoption of advanced diagnostic imaging technologies and increased prevalence of cancer across North America are accelerating the use of nuclear medicine. In 2024, Siemens Healthineers launched new PET/CT systems improving diagnostic accuracy, thus driving greater adoption across oncology and neurology applications.
- Expansion of radioisotope production capabilities by major players such as NorthStar Medical Radioisotopes is improving supply reliability. Their 2024 announcement of new Mo-99 production facilities in the U.S. directly addresses the shortage crisis and enhances market accessibility.
Key Trends
- Growing integration of artificial intelligence into nuclear medicine workflows is optimizing image analysis and improving predictive outcomes. GE Healthcare's 2024 release of an AI-powered platform demonstrates accelerating digitalization in the sector.
- Rapid expansion of theranostics—combining diagnostics and therapeutics—led by Curium Pharma’s advances in targeted radiotherapies, is contributing to personalized oncology, making treatments more precise and effective.
Key Opportunities
- Increased investment in cyclotron and radiopharmacy infrastructure, as evidenced by Bracco Imaging's 2024 North American expansion, is expected to unlock greater clinical availability and research applications for novel isotopes.
- Rising demand for personalized medicine and molecular imaging opens new avenues for biotech collaborations, with Lantheus Holdings partnering with academic centers in 2024 to advance targeted imaging agents.
Key Challenges
- Frequent supply chain disruptions for critical isotopes pose a consistent challenge, as seen with Mallinckrodt’s 2024 capacity constraints, which created temporary shortages for major hospitals.
- Complex regulatory processes for new radioisotope approvals delay market entry. Jubilant Radiopharma faced multi-year timelines for regulatory clearance, impacting innovation speed.
Key Restraints
- High cost of cyclotron installation and radiopharmaceutical production remains restrictive for small and medium providers. Nordion’s reporting in 2024 indicated substantial capital barriers for entry and expansion.
- Stringent regulatory and radioactive handling requirements demand significant compliance investments; this was highlighted in 2024 by new NRC rules impacting operational flexibility for radiopharmacies.
Market Share by Type, 2025
The North America Nuclear Medicine & Stable Isotopes Market by type is dominated by diagnostic applications, reflecting the broad deployment of imaging agents in clinical practice. This segment commands over half of the total market due to ongoing advances in PET and SPECT technologies and their routine use in oncology and cardiology. Therapeutic uses are also expanding, driven by new approvals in targeted radionuclide therapies. Research and industrial types have a smaller yet significant presence, supporting innovation and non-medical isotope usage. The market breakdown demonstrates a well-established foothold for diagnostics with growth potential in therapy and research sectors.
Market Share by Applications, 2025
Oncology continues to be the predominant application of nuclear medicine and stable isotopes in North America, reflecting their essential role in cancer diagnosis and therapy. Cardiology is the second largest segment, supporting the evaluation of myocardial health and perfusion studies. Neurology applications are on the rise as novel tracers for Alzheimer’s and Parkinson’s gain ground. Other areas like thyroid and orthopedics constitute a smaller share but remain important for the diversification of nuclear medicine’s clinical reach.
Market Revenue (USD Million), 2020-2035
The revenue trajectory of the North America Nuclear Medicine & Stable Isotopes Market from 2020 to 2035 shows continuous growth as medical and research demands rise. The market is estimated at USD 7,450 Million in 2025 and is projected to surpass USD 15,200 Million by 2035, reflecting a robust CAGR driven by expanding clinical applications, increased access to isotopes, and steady adoption of next-generation technologies. This sustained growth underlines the critical importance of both diagnostic and therapeutic nuclear medicine to modern healthcare.
Year-on-Year Growth (%), 2020-2035
The YOY growth of the North America Nuclear Medicine & Stable Isotopes Market has been steady, averaging 7.2% between 2020 and 2025, and is expected to trend at approximately 6% through 2035. Peaks are projected in periods of major technological introductions, such as new PET tracers or theranostics. However, the market may experience brief slowdowns due to regulatory changes or supply disruptions, before rebounding with subsequent innovation and commercialization cycles.
Market Share by Regions, 2025
Among North American countries, the United States commands the largest share by a wide margin, owing to its advanced healthcare system, abundant nuclear medicine facilities, and presence of major pharmaceutical and biotech companies. Canada occupies the second largest portion, supported by government-funded research and isotope production, while Mexico’s market, though smaller, is witnessing expansion due to increasing healthcare investments.
Market Players Share, 2025
The market is highly consolidated, with Cardinal Health leading at 19%, followed by Siemens Healthineers and Curium Pharma, holding 15% and 13% respectively. GE Healthcare, Bracco Imaging, and Nordion collectively comprise a significant share, while a competitive fringe of specialized manufacturers and distributors rounds out the market. This landscape highlights the dominance of established multinationals alongside rising regional innovators.
Market Buyers Share, 2025
Hospitals & clinics form the primary customer base, responsible for 63% of purchases due to the high utilization of nuclear medicine in clinical diagnostics and treatment. Research institutions and contract research organizations account for 15% as they expand their usage of stable isotopes and imaging agents in R&D activities. Direct tenders and government buyers, including public health initiatives and academic medical centers, make up the remainder, reflecting efforts to broaden access and innovation.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 7450 |
| Regions | United States, Canada, Mexico |
| Segments | Type: Diagnostic, Therapeutic, Research, Industrial, Others; Application: Oncology, Cardiology, Neurology, Thyroid, Orthopedics, Others |
| Players | Cardinal Health, Siemens Healthineers, Curium Pharma, Nordion, Lantheus Holdings, Bracco Imaging, NTP Radioisotopes, Eckert & Ziegler, GE Healthcare, Jubilant Radiopharma, Pharmalucence, Mallinckrodt, Advanced Accelerator Applications, NorthStar Medical Radioisotopes, IsoTex Diagnostics |
Key Recent Developments
- June 2024: Siemens Healthineers announces FDA clearance of their next-gen PET/CT system for advanced oncology imaging.
- July 2024: NorthStar Medical Radioisotopes reports successful commissioning of U.S.-based Mo-99 radioisotope production facility.
- August 2024: GE Healthcare launches an AI-assisted image analysis platform for nuclear medicine, enhancing workflow efficiency.
- September 2024: Bracco Imaging expands its radiopharmaceuticals manufacturing capabilities in North America to meet rising demand.
- October 2024: Curium Pharma receives approval for novel targeted radiotherapeutic agent for prostate cancer treatment in the United States.
